Pharmaceuticals, Biotechnology and Life Sciences
Bristol Myers Squibb presented results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab)…
Opdivo in combination with cisplatin-based chemotherapy followed by Opdivo monotherapy reduced the risk of death by 22% for patients with…
Neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo reduced the risk of disease recurrence, progression or death by…
The European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the adjuvant treatment of adults and adolescents 12 years of age and older with stage IIB or IIC melanoma who have undergone complete resection
The European Commission (EC) has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression ≥ 1%.
The European Medicines Agency (EMA) has validated Bristol Myers Squibb-s type II variation application for Opdivo (nivolumab) in combination with chemotherapy for the neoadjuvant treatment of patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC), based on results from the CheckMate -816 trial.
The U.S. Food and Drug Administration had approved the expanded use of Opdivo, BMS’s cancer drug for patients with an aggressive form of lung cancer.
Opdivo in combination with Cabometyx was generally well tolerated, with a low rate of treatment-related discontinuations.
UbiVac has announced working with BMS on Phase Ib study to combine UbiVac’s DRibble® Platform Vaccine, DPV-001 with anti-OX40 (BMS-986178) and Opdivo (nivolumab) to test hypothesis that this combination will augment anticancer immunity in advanced triple negative breast cancer.
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) flat…